Brian Goff - Jun 13, 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jun 13, 2024
Transactions value $
$0
Form type
4
Date filed
6/17/2024, 05:14 PM
Previous filing
Jun 7, 2024
Next filing
Aug 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +15.4K $0.00 15.4K Jun 13, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +22.3K $0.00 22.3K Jun 13, 2024 Common Stock 22.3K $25.96 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 This option was granted on June 13, 2024 with respect to 22,297 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on June 13, 2025 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter.